Lord, Abbett & Co
TNGX icon

Lord, Abbett & Co’s Tango Therapeutics TNGX Stock Holding History

Lord, Abbett & Co’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6M Buy
+532,109
New +$13.2M 0.05% 324

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Lord, Abbett & Co's TNGX Position: Q2 2026 in Review

Lord, Abbett & Co opened a new position in Tango Therapeutics (TNGX) in Q2 2026: 532,109 shares worth $16.6M. The stake represents 0.05% of the portfolio and ranks #324 among its holdings.

247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Lord, Abbett & Co held 532,109 shares of Tango Therapeutics worth $16.6M as of Q2 2026.
  • Tango Therapeutics was a new Lord, Abbett & Co position in Q2 2026.
  • Tango Therapeutics made up 0.05% of Lord, Abbett & Co's portfolio in Q2 2026, its #324 holding.
  • 247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.